The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Turning thet tide against tuberculosis . As the world's deadliest infectious disease surges, GSK and partners are pioneering ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Endurance Techn, Solar Ind, GlaxoSmithKline, Gland, and Motilal Oswal marked their presence among the top gainers in the ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Migraine is recognized globally as the seventh most disabling condition across all diseases, accounting for approximately 2.9% of all years lived with disability (YLDs). It is also the top cause of ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The risk of mortality among older adults hospitalized with influenza was significantly lower among those who received oseltamivir vs no antiviral therapy.

Peter Humphrey, a former journalist and private investigator, believes a Chinese surveillance team were monitoring his group ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Sexual health services in the UK will start rolling out a 'world-first' vaccine programme designed to protect people from ...